Avidity analytics for immunotherapy development
Avigen is a preclinical Contract Research Organisation offering cell and biologics avidity analysis services. We enable you to identify your most potent immunotherapy — before you commit to costly in vivo studies.
Preclinical Contract Research Organisation
Accelerate your immunotherapy
breakthroughs with Avigen
technologyA new dimension in immunotherapy R&D
Our platform redefines how potent immune cells are identified—measuring cellular avidity to uncover what truly drives therapeutic success.
Physiological Relevance
Captures the full complexity of live immune–target cell interactions, delivering insights that better reflect in-vivo therapeutic behaviour.
High Throughput
Analyses tens of thousands of single-cell interactions per run—and scales to millions, enabling comprehensive profiling of diverse immune cell populations.
Gentle
Maintains cell viability and functionality for immediate downstream testing, seamlessly integrating into your existing R&D pipeline.
Fully Adaptable
Compatible with a wide range of adherent target cells and immune cell types, including TCR-T, CAR-T, NK, and beyond—across various solid tumour indications.
servicesPreclinical avidity services for every stage of your programme
From initial lead identification through to pre-IND candidate confirmation, our platform adds a layer of translational insight that standard assays cannot provide — helping you advance the right candidates with confidence.
technologyA new dimension in
immunotherapy R&D
Our platform redefines how potent immune cells are identified—measuring cellular avidity to uncover what truly drives therapeutic success.
Physiological Relevance
Captures the full complexity of live immune–target cell interactions, delivering insights that better reflect in-vivo therapeutic behaviour.
High Throughput
Analyses tens of thousands of single-cell interactions per run—and scales to millions, enabling comprehensive profiling of diverse immune cell populations.
Gentle
Maintains cell viability and functionality for immediate downstream testing, seamlessly integrating into your existing R&D pipeline.
Fully Adaptable
Compatible with a wide range of adherent target cells and immune cell types, including TCR-T, CAR-T, NK, and beyond—across various solid tumour indications.
Avigen was highly professional and a pleasure to work with, delivering high-quality data on a rapid timeline. Their avidity-based analysis provided valuable insight beyond standard assays and provided a new layer of validation data for future decision-making.
Avigen approached our project with strong attention to detail and scientific integrity. Their careful optimisation of difficult assay conditions ensured in reliable, robust data that we could trust. The avidity readouts holistically captured meaningful aspects of functional immune–target engagement that was previously difficult to evaluate, adding a new layer of validation to our preclinical R&D. Interactions with the team were consistently positive and enjoyable. I would strongly recommend the team and their platform.
testimonialsTrusted by scientists developing
the next generation of therapies
testimonialsHear what our customers say about us
"Avigen was highly professional and a pleasure to work with, delivering high-quality data on a rapid timeline. Their avidity-based analysis provided valuable insight beyond standard assays and provided a new layer of validation data for future decision-making.”
partnersOur partners












